PBRM1 Biomarkers Predict Anti-Immune Checkpoint Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy for renal cell carcinoma (RCC) lacks predictive biomarkers for response to immune checkpoint therapies, such as anti-PD-1 treatments, making it difficult to identify which patients will benefit from these therapies and which will not.
Innovation Solution
The discovery of loss-of-function mutations in the PBRM1 gene as a specific biomarker to predict clinical outcomes in RCC patients treated with immune checkpoint therapies, allowing for the identification of patients likely to respond or not respond to these treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint therapies are administered to RCC patients, then tumor response rates improve compared to traditional therapies, but the lack of predictive biomarkers makes it difficult to identify which patients will benefit
Solution Approach 1:
The patent performs preliminary genetic analysis of PBRM1 mutations before administering immune checkpoint therapy to identify patients who are likely to respond. This advance characterization of tumor genetics allows clinicians to predict treatment outcomes beforehand, resolving the contradiction by providing predictive information before treatment decisions are made.
Solution Approach 2:
The patent introduces PBRM1 mutation status as an intermediary biomarker that mediates between the tumor's genetic characteristics and the clinical response to immune checkpoint therapy. This intermediary provides the missing predictive information by serving as a measurable indicator that links tumor biology to treatment efficacy.
2Ease of operation
If PD-L1 immunohistochemistry is used to predict treatment response, then a simple diagnostic test is available, but it fails to predict treatment response in RCC patients
Solution Approach 1:
The patent changes the diagnostic parameter from PD-L1 protein expression levels to PBRM1 genetic mutation status. This parameter change improves measurement precision for predicting treatment response, as PBRM1 mutations are strongly associated with sensitivity to immune checkpoint blockade, while maintaining relative ease of operation through standardized genetic testing methods.
3Productivity
If immune checkpoint therapy is given to all RCC patients, then all patients receive potentially beneficial treatment, but non-responders waste treatment resources and experience unnecessary side effects
Solution Approach 1:
The patent performs preliminary PBRM1 mutation analysis to stratify patients into likely responders and non-responders before treatment. This preliminary action increases treatment resource efficiency by directing immune checkpoint therapy primarily to patients with PBRM1 mutations who are most likely to benefit, while reducing exposure in patients unlikely to respond.
Solution Approach 2:
The patent applies personalized treatment based on local tumor characteristics - specifically, the presence or absence of PBRM1 mutations in each patient's tumor. This local quality approach ensures that treatment decisions are tailored to the specific genetic profile of each tumor, improving both resource efficiency and treatment benefit certainty.
Data Source
AI summary
The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.